| T76776 |
Emactuzumab
|
1448221-67-7
|
98%
|
|
|
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumo...
|
| T5172 |
AZ304
|
942507-42-8
|
98%
|
|
|
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
|
| T4315 |
Ki20227
|
623142-96-1
|
|
|
|
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451...
|
| T2116 |
AEE788
|
497839-62-0
|
|
|
|
AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
| T35570 |
Chiauranib
|
1256349-48-0
|
96.25%
|
|
|
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
|
| T64066 |
CSF1R-IN-3
|
2760584-90-3
|
97.31%
|
|
|
CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM. CSF1R-IN-3 has anti-proliferative activity against colorectal cancer cells. CSF1...
|
| T10775 |
C-Fms-IN-2
|
791587-67-2
|
97.34%
|
|
|
c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).
|
| T6028 |
PF 477736
|
952021-60-2
|
98.34%
|
|
|
PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CS...
|
| T10894 |
CSF1R-IN-1
|
2095849-04-8
|
98.57%
|
|
|
CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.
|
| T15199 |
Edicotinib
|
1142363-52-7
|
98.58%
|
|
|
Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effect...
|
| T7100 |
PLX5622
|
1303420-67-8
|
98.83%
|
|
|
PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor.
|
| T6119 |
Sotuletinib
|
953769-46-5
|
98.83%
|
|
|
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase...
|
| T10652 |
Vimseltinib
|
1628606-05-2
|
98.98%
|
|
|
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM).
|
| T6104 |
Cerdulatinib hydrochloride
|
1369761-01-2
|
99.23%
|
|
|
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
|
| T2514 |
Linifanib
|
796967-16-3
|
99.29%
|
|
|
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDG...
|
| T4376 |
Nampt-IN-1
|
1698878-14-6
|
99.4%
|
|
|
Nampt-IN-1 (LSN3154567) (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
|
| T3351 |
Onatasertib
|
1228013-30-6
|
99.41%
|
|
|
Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the i...
|
| T2659 |
GW2580
|
870483-87-7
|
99.48%
|
|
|
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
|
| T2115 |
Pexidartinib
|
1029044-16-3
|
99.66%
|
|
|
Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antin...
|
| T6930 |
Pazopanib Hydrochloride
|
635702-64-6
|
99.69%
|
|
|
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM...
|
